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Arginine:glycine amidinotransferase (AGAT) catalyzes the first step of creatine synthesis, resulting in the formation
of guanidinoacetate, which is a substrate for creatine formation. In two female siblings with mental retardation
who had brain creatine deficiency that was reversible by means of oral creatine supplementation and had low
urinary guanidinoacetate concentrations, AGAT deficiency was identified as a new genetic defect in creatine me-
tabolism. A homozygous G-A transition at nucleotide position 9297, converting a tryptophan codon (TGG) to a
stop codon (TAG) at residue 149 (T149X), resulted in undetectable cDNA, as investigated by reverse-transcription
PCR, as well as in undetectable AGAT activity, as investigated radiochemically in cultivated skin fibroblasts and
in virus-transformed lymphoblasts of the patients. The parents were heterozygous for the mutant allele, with
intermediate residual AGAT activities. Recognition and treatment with oral creatine supplements may prevent
neurological sequelae in affected patients.
The creatine/creatine-phosphate system plays an impor-
tant role in the storage and transmission of phosphate-
bound energy (fig. 1). In humans, creatine is synthesized
mainly in the liver and pancreas, in a process involving
two reactions catalyzed by arginine:glycine amidino-
transferase and by guanidinoacetate methyltransferase
(Walker 1979). Creatine is transported via the blood,
and its accumulation in the main target organs—the
muscle and brain—is provided by an active transport
process (Guimbal and Kilimann 1993) mediated by the
creatine transporter protein (Sora et al. 1994). Guani-
dinoacetate methyltransferase (GAMT [MIM 601240])
deficiency is the first inborn error of creatine metabolism
(von Figura et al. 2000), originally recognized in two
unrelated patients with mental retardation, epilepsy,
and extrapyramidal symptoms (Sto¨ckler et al. 1996b).
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GAMT deficiency is characterized by accumulation of
guanidinoacetate, which is the substrate for the activity
of the deficient enzyme (Ganesan et al. 1997; Schulze et
al. 1997; Sto¨ckler et al. 1997; Leuzzi et al. 2000; van
der Knaap et al. 2000), as well as by severe brain creatine
deficiency, which is reversible by means of oral creatine
substitution (Sto¨ckler et al. 1994, 1996a). Recently, a
second inborn error of creatinemetabolism, theX-linked
creatine transporter (MIM 300036) defect, has been de-
scribed in a boy with mental retardation (Salomons et
al. 2001). In the patients with the X-linked creatine
transporter defect, brain creatine deficiency is not re-
versible by oral creatine substitution (Cecil et al. 2001).
Bianchi et al. (2000) reported two female siblings,
aged 4 and 6 years, with mental retardation and severe
creatine deficiency in the brain. At the time of the present
study, the molecular cause of the creatine deficiency syn-
drome in these two siblings remained unidentified:
GAMT deficiency was excluded by the presence of nor-
mal enzyme activity, as measured in virus-transformed
lymphoblasts (table 1), and X-linked creatine trans-
porter deficiency was unlikely because of a prompt in-
crease of brain creatine by means of oral creatine sub-
stitution. Retrospective investigation of the patients’
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Figure 1 Metabolic pathway of creatine/phospho-creatine.
CRTR, creatine transporter; CK, creatine kinase.
Table 1
AGAT and GAMT activity and Urinary Guanidinoacetate
Concentrations in Two Female Siblings with AGAT Deficiency
ACTIVITY
(nmol/hr/mg protein)
GUANIDINOACETATE
EXCRETION IN URINE
(mmol/g creatinine,
mmol/liter)AGAT GAMT
Patient 1 !.3 .53 16, 13
Patient 2 !.3 .64 17, 9
Father 4.9 ND ND
Mother 6.3 ND ND
Controls 12.6–23.4a .61–.84b 60–850, 50–500
NOTE.—Enzyme extracts were obtained from virus-transformed
lymphoblasts by filtration (Millipore, cutoff 10,000 Daltons) of cell
homogenate supernatants in 0.1 M Tris/HCl pH 8.0, 2 mM DTT, 0.1
mM EDTA, and incubated for 6 h with 100 mM arginine and 14C-
glycine (3 mCi/ml). The formation of guanidinoacetate was measured
by determination of radioactivity (14C) in the guanidinoacetate fraction
after separation from glycine by high-performance liquid chromatog-
raphy (Hypersil ODS reverse-phase column, 250#4 mm, 5 mm, Hew-
lett-Packard). The formation of guanidinoacetate was proportional to
incubation time (provided that incubation time did not exceed 6 h)
and to the amount of sample extract (provided that substrate turnover
was not 110%). GAMT activities were determined as described by
Ilas et al. (2000). Guanidinoacetate concentrations were measured in
24-h urine samples, by GC-MS (Hunneman and Hanefeld 1997) and
by stable-isotope dilution (Struys et al. 1998). NDp not determined.
a .np 5
b .np 8
biological material finally disclosed extremely low levels
of urinary guanidinoacetate excretion (table 1), which,
together with the absent resonance of creatine/creatine
phosphate in the brain, as shown by in vivo proton mag-
netic resonance spectroscopy (Bianchi et al. 2000), is a
diagnostic indicator of arginine:glycine amidinotrans-
ferase (AGAT [MIM 602360]) deficiency. AGAT defi-
ciency is a novel disorder of creatine synthesis, which,
until now, has not been described in humans. AGAT
catalyzes the first of the two reactions in creatine bio-
synthesis, including the transfer of the amidino group
from arginine to glycine, to form ornithine and gua-
nidinoacetate, the immediate precursor of creatine.
The human AGAT gene is localized on chromosome
15q15.3, and its genomic sequence has recently been
identified (AGAT genomic DNA [GenBank accession
number 1432573]). The AGAT genomic DNA is 16,858
bp long and consists of nine exons.
To further test the hypothesis that the creatine defi-
ciency in both of these patients is due to AGAT defi-
ciency, we first screened exon 1 by direct sequencing and
screened exons 2–9 and adjoining introns of the human
AGAT gene by denaturing gradient gel electrophoresis
(DGGE) (for primer sequences and DGGE conditions,
see table 2). Investigation of the PCR product from exon
3 of the AGAT gene in both patients revealed a single
band whose position on DGGE differed from that of the
wild-type allele (fig. 2, lanes 2, 3, and 5), whereas the
bands representing the PCR products from the remain-
ing exons did not differ from the wild-type alleles (data
not shown). DGGE analysis in DNA samples from both
parents showed two bands: one characteristic of the
wild-type allele and the other identical to the mutant
allele found in both index patients (fig. 2, lanes 1 and
4). Sequencing of all putative sequence variations as
pointed out by the DGGE analysis confirmed patients 1
and 2 to be homozygous for a GrA transition at nu-
cleotide position 9297, which converts a tryptophan
(TGG) codon to a stop (TAG) codon at residue 149
(T149X) (fig. 3a). This nucleotide change predicts a se-
verely truncated protein that lacks the active-site cysteine
residue 407 on exon 9 (Humm et al. 1997). Sequence
analysis of the parents’ DNA showed heterozygosity for
the wild-type and the mutant nucleotide sequence (fig.
3c).
To investigate the effect of the genomic 9297 GrA
nucleotide change at the cDNA level, we analyzed total
lymphoblast RNA of both patients and of an unaffected
Table 2
Oligonucleotide Primers for the Amplification of Exons 1–9 of the AGAT Gene and Respective DGGE Conditions
FRAGMENT
PRIMER SEQUENCEa
LENGTH OF
AMPLIFIED
SEGMENT
(bp)
DENATURANT
RANGE
(%)
MELTING
POINT
(C)
PCR ANNEALING
TEMPERATURE
(C)Forward Reverse
Exon 1 5′-CACCACCTGTTCCCGGCAGC-3′ 5′-TCTCGTGCAATTCCGGCTAG-3′ 381 NAb 85 64
Exon 2 5′-CTGATAGAGCAATGCAATAC-3′ 5′-(GC)AAGCAGTCAGAGGGTAGCAG-3′ 337 25–65 76 55
Exon 3a, 5′ end 5′-TAAGTATTGTGTTTATTTGC-3′ 5′-(GC)CTTCAATGACCAGTCAATGG-3′ 240 15–55 68 50
Exon 3b, 3′ end 5′-ATTGAAGAAATGTGCAATAT-3′ 5′-(GC) AGCTTTCCCCTTACACATTA-3′ 220 15–55 69 50
Exon 4a, 5′ end 5′-(GC)ACACTACTGAAGTTGTCATG-3′ 5′-TAAAGCTCATCAGCCATTGT-3′ 263 25–65 73 55
Exon 4b, 3′ end 5′-TCACGCTTCTTTGAGTACCG-3′ 5′-(GC)ACTCTTTGTGGATCATTTAG-3′ 213 25–65 72 60
Exon 5 5′-(GC)TTCTCATGATCCAGTGCATT-3′ 5′-TTTTAATTTGGAAGTAAAGA-3′ 289 25–65 72 50
Exon 6 5′-(GC)AATATTTATCGATCGTATGT-3′ 5′-TTAAAATAAAAGTGGCAATT-3′ 314 25–65 71 50
Exon 7 5′-(GC)TGATAAGGGCTATTAGAGAC-3′ 5′-AAGCACCACTTCACACCTTA-3′ 317 15–55 67 60
Exon 8 5′-TCTTCACTTGTAAATCCTTG-3′ 5′-(GC)TAACTTGGTGCCTCTAAAAG-3′ 360 15–55 67 55
Exon 9a, 5′ end 5′-GAACCACAGGACTCCTCCAA-3′ 5′-(GC)TAGGACTGTAAGGTGCCTCG-3′ 238 15–55 69 60
Exon 9b, 3′ end 5′-TTCGTAATGCCAATTCCCTG-3′ 5′-(GC)AAAGCACTACAGTTCATGCA-3′ 230 25–65 75 60
NOTE.—GC clamp p 5′-CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCG-3′.
a Primer sequences according to human genomic AGAT gene sequence. All primers are intronic, with the exception of reverse primers of exons 3a, 4a, 9a and forward
primers of exons 3b, 4b, 9b, which were placed on exon regions.
b NA p not analyzed by DGGE, but directly sequenced.
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Figure 2 Identification of AGAT nonsense mutation in lymphoblasts of two female siblings and leukocytes of their parents, by DGGE
analysis of exon 3. Lane 1, Father, genotype T149X/N. Lane 2, Patient 1, genotype T149X/T149X. Lane 3, Patient 2, genotype T149X/T149X.
Lane 4, Mother, genotype T149X/N. Lane 5, Wild-type DNA from unaffected control, genotype N/N. DNA extraction from EBV-transfected
lymphoblasts and cultivated fibroblasts was performed using guanidinhydrochloride/proteinase K (Nucleospin CT kit [Machery Nagel]). PCR
primers were designed to cover exons 1–9 and the adjoining introns of the AGAT gene. PCR reactions were carried out over 37 cycles with
2.5 U of Ampli-Taq Gold DNA polymerase (Perkin Elmer) in a Perkin-Elmer-Cetus DNA Thermal Cycler. DGGE analysis of PCR products
was essentially performed as described by Greber-Platzer et al. (1997), after heteroduplex formation by loading 20 ml of sample onto an 8%
polyacrylamide gel containing a 15%–55% or 25%–65% linearly increasing denaturing gradient (100% p 7 M urea and 40% (vol/vol)
deionized formamide). Electrophoresis was performed at 160 V for 6 h in a 1# TAE buffer at 60C, using a DCode system (Biorad). After
electrophoresis, gels were stained in ethidium bromide and examined under ultraviolet illumination. DGGE analysis of exon 1 was not possible,
because of its high melting temperature; therefore, direct sequencing of exon 1 was performed. In the patients, no aberrations from the normal
sequence were found on exon 1.
control sample, by means of PCR following reverse tran-
scription (RT-PCR). When primers flanking the entire
cDNA sequence of the AGAT gene were used (AGAT
mRNA [GenBank accession number S68805]), no tran-
script was detected at the cDNA level in the patients,
whereas a normal-sized 1,664-bp cDNA sequence was
detected in the unaffected control sample (fig. 4, lanes
2, 3, and 4). To exclude the possibility that 40 rounds
of RT-PCR did not yield enough product from both pa-
tients, 35 additional rounds of PCR were performed,
using a second pair of primers nested within the first
primer pair. This again revealed no detectable cDNA in
the patients, as well as the expected 1,145-bp cDNA in
the unaffected control sample (fig. 4, lanes 5, 6, and 7).
The finding of no detectable cDNA by RT-PCR suggests
either complete absence of the AGAT gene or the pres-
ence of unstable RNA transcripts in the affected patients,
which are subject to nonsense-mediated decay (Osborn
and Upadhyaya 1999). To investigate the effect of the
gene mutation at the translational level, we measured
the biological activity of AGAT enzyme protein in cul-
tivated fibroblasts and in virus-transformed lympho-
blasts from both patients and their parents, by a ra-
diochemical assay based on the separation, by high-
performance liquid chromatography (HPLC), of ra-
dioactively labeled substrate from reaction product.
Whereas AGAT activity was clearly measurable in nor-
mal control cell lines, no detectable activity was found
in the cell extracts from the patients (table 1). Cell ex-
tracts from both parents showed intermediate residual
activity, as would be expected in the heterozygous state.
In addition to GAMT and creatine transporter defi-
ciency, AGAT deficiency has been predicted as the third
inborn error of creatine metabolism causing cerebral cre-
atine deficiency syndromes (Sto¨ckler-Ipsiroglu 1997). In
the present report on two siblings with mental retar-
dation, we have finally demonstrated AGAT deficiency
as the third inborn error of creatine synthesis. In both
patients, we were able to show by RT-PCR that the ho-
mozygous mutation resulting in a stop codon on exon
3 results in complete absence of AGAT or in unstable
transcripts without detectable functional activity at the
enzyme protein level. These findings confirm that the
genomic mutation found in both patients fulfills the dis-
ease-causing criteria as described elsewhere (Cotton and
Scriver 1998). Heterozygosity for the mutant allele and
intermediate residual AGAT activities in the clinically
asymptomatic parents indicate autosomal recessive in-
heritance of AGAT deficiency.
In both patients, deficient guanidinoacetate produc-
tion was clearly reflected by extremely low plasma and
urinary guanidinoacetate concentrations. Therefore, as-
sessment of guanidinoacetate concentrations in body flu-
ids may represent a valuable tool for identification of
patients at risk. Care must be taken to choose a method
that is sensitive enough to safely detect values below the
normal range. The gas chromatographic–mass spectro-
metric (GC-MS) stable-isotope dilution method (Struys
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Figure 3 Direct sequencing of PCR products showing putative sequence variations, as pointed out by DGGE analysis, was performed by
double-stranded automated cycle sequencing of the PCR products on a ABI 370 sequencer (Applied Biosystems). a, Patients 1 and 2. b, Control.
c, Parents.
et al. 1998), as applied in these patients, as well as iso-
tope dilution electrospray tandem mass spectrometry
(Bodamer et al. 2001), may represent such methods. In
contrast, accumulation of glycine and arginine, which
are substrates for activity of the deficient enzyme, are
alternatively metabolized. Therefore, significant accu-
mulation of these amino acids does not occur, and amino
acid analysis will not identify patients at risk for AGAT
deficiency. Plasma creatine concentrations were report-
ed to be normal in both patients (Bianchi et al. 2000);
therefore, determination of plasma creatine concentra-
tions may not be useful as a screening test for AGAT
deficiency.
To provide a noninvasive diagnosis of human AGAT
deficiency, we have developed a sensitive enzyme assay
for the determination of AGAT activity in cultivated fi-
broblasts and in virus-transformed lymphoblasts, by ra-
dioactive-substrate labeling of glycine and separation,
by HPLC, of radioactivity in the guanidinoacetate frac-
tion. By this method, the radioactivity in the guanidi-
noacetate fraction of the reaction samples from normal
controls was ∼30 times higher than the radioactivity
found in the respective blank samples. This high sensi-
tivity was the prerequisite for reliable measurements in
fibroblasts and lymphoblasts, which have a lower ex-
pected expression of enzyme activity, as compared with
organs like liver, kidney, and pancreas, which have the
highest activity levels in the body (Van Pilsum et al.
1972).
The DGGE method, in comparison with other mu-
tation screening methods, detects almost 100% of mu-
tations, requires no label, and separates mutant mole-
cules from wild-type molecules for analysis (Cotton
2000). In the DGGE method developed for mutation
screening of AGAT deficiency, increased electrophoretic
resolution was achieved by heteroduplex formation. As
a result, the zygosity of the patient sample could rapidly
be determined before final confirmation by sequencing
(Guldberg and Gu¨ttler 1993)
In both patients, almost complete restoration of ex-
tremely low pretreatment cerebral creatine levels by
means of oral creatine supplementation was paralleled
by a favorable clinical response, as shown by significant
improvement of highly abnormal developmental scores
(Bianchi et al. 2000). This observation suggests that
AGAT deficiency is a treatable inborn error of creatine
synthesis and that early recognition and treatment of
this disease might effectively prevent neurological se-
quelae. Determination of guanidinoacetate in body flu-
ids, the enzyme assay and DGGE mutation screening
method developed for the biochemical and molecular
characterization of the first two index patients, will pro-
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Figure 4 RT-PCR analysis to examine the expression of the T149X allele in lymphoblasts of both siblings. Lane 1, 100-bp DNA ladder.
Lane 2, RT-PCR, patient 1. Lane 3, RT-PCR, patient 2. Lane 4, RT-PCR, unaffected control. Lane 5, Nested PCR, patient 1. Lane 6, Nested
PCR, unaffected control. Lane 7, Nested PCR, patient 2. Total RNA extraction was performed from EBV-transfected lymphoblasts (Molecular
Research Center, Inc.), using RNAzolB. A one step RT-PCR was performed using the Qiagen kit (Qiagen, Inc.). Two micrograms of the extracted
RNA in aqueous solution was reverse transcribed in a volume of 50 ml containing 800 nM each of the AGAT specific primers on the 5′-UTR
and 3′-UTR of the total RNA (forward primer: 5′-GAGCGACGCGGCCCAGAGGCCAGGAACATT-3′; reverse primer: 5′-CCTTTTGGAAAGA-
AAATTAAAAACAGAGGT-3′), 400 mM of each dNTP, 10 U of RNase inhibitor, 10 ml of 5# Qiagen buffer, and 2 ml RT-PCR enzyme mix,
at 50C for 30 min. A PCR activation step at 95C for 15 min and 40 cycles of PCR consisting of denaturation at 94C for 1 min, annealing
at 65C for 1 min, extension at 72C for 1 min, followed by a final elongation at 72C for 10 minutes were performed (PCR product 1,664
bp). In a second round of PCR, 35 cycles were performed in a PCRmixture containing 0.5 ml of PCR product from the first round of amplification,
400 nM of each nested primer on exons 1 and 9 (forward primer: 5′-ATGCTGCGGGTGCGGTGTCTGCGCGGCGGG-3′; reverse primer: 5′-
ATCTTTTGAATTGGAACTTCATTGGCATCC-3′), 10 mMTris-HCl, pH 8.3, 1.5mMKCl, 2mMMgCl2, 200 mMof each deoxyribonucleotide,
and 2.5 U of AmpliTaq Gold DNA polymerase in a volume of 50 ml (PCR product 1,145 bp) . RT-PCR products were run on a 1% agarose
gel and were visualized by ethidium bromide staining.
vide valuable tools for the noninvasive diagnosis of this
new disorder.
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